According to a recent LinkedIn post from Monarch Medical Technologies, the company is emphasizing the adaptive capabilities of its EndoTool insulin dosing platform. The post notes that EndoTool recalculates insulin sensitivity, residual insulin, and patient response on a dose‑by‑dose basis to adjust recommendations in real time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content also suggests that the platform is positioned for complex inpatient care scenarios, including renal insufficiency, dialysis, steroid‑induced hyperglycemia, DKA, HHS, and tube feeds or TPN. By highlighting integration with Glooko’s inpatient solution, the post points to a broader ecosystem play that could enhance product stickiness, support hospital adoption, and potentially drive recurring software revenue in a niche but high‑acuity segment of the glycemic management market.